Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

MSP-2020

From Wikipedia, the free encyclopedia

Pharmaceutical compound
MSP-2020
Clinical data
Other namesMSP2020
Routes of
administration
Oral[1]
Drug classSerotonin receptor agonist;Serotonin 5-HT2A receptor agonist;Serotonergic psychedelic;Hallucinogen
ATC code
  • None

MSP-2020 is apsychedelic drug of thetryptamine andpyrrolidinylmethylindole families related topsilocybin which is under development for the treatment ofmental disorders such asmajor depressive disorder.[1][2][3][4][5][6][7] It is takenorally.[1] The drug acts as aserotonin 5-HT2A receptor agonist and is described as aprodrug.[1][3][8] It is a 3-pyrrolidineindolederivative and hencecyclized tryptamine and is said to bepsilocybin-like but with stronger effects and a shorterduration.[1][5][6][7] MSP-2020 was originated by Mindset Pharma and is now under development byOtsuka America Pharmaceutical, which acquired Mindset Pharma in January 2024.[1][2][3][4] As of January 2026, MSP-2020 is inphase 1clinical trials for major depressive disorder.[1][2][3] MSP-2020 waspatented by Mindset Pharma in 2021, though its specificchemical structure has not been disclosed and is unclear.[1][7][5][6]

See also

[edit]

References

[edit]
  1. ^abcdefgh"MSP 2020".AdisInsight. 14 January 2026. Retrieved15 January 2026.MSP 2020 is an oral pyrrolidine-indole derivative psilocybin like high potency, short acting drug being developed by Otsuka America [...]
  2. ^abc"Delving into the Latest Updates on MSP-2020 with Synapse".Synapse. 12 January 2026. Retrieved15 January 2026.
  3. ^abcd"MSP-2020 Drug Profile".Ozmosi. Retrieved15 January 2026.
  4. ^ab"Otsuka makes psychedelics play, buying Mindset".pharmaphorum. September 2023. Retrieved15 January 2026.To date, Otsuka has been working with Mindset on the company's second family of psilocybin-based drug candidates led by MSP-2020 and back-up compound MSP-2003, which offer "greater potency than LSD combined with a shorter psychedelic effect than psilocybin."
  5. ^abcSabnis RW (January 2025)."Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder".ACS Medicinal Chemistry Letters.16 (1):18–19.doi:10.1021/acsmedchemlett.4c00581.PMC 11726355.PMID 39811142.
  6. ^abc"3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders".Google Patents. 4 February 2021. Retrieved15 January 2026.
  7. ^abcPharma M (5 October 2022)."Mindset Pharma Selects Lead Clinical Candidates From "Family 2" of its Next Generation Psychedelic Drug Portfolio".GlobeNewswire News Room (Press release). Retrieved15 January 2026.MSP-2020 and MSP-2003, exhibiting a stronger and shorter acting psychedelic effect than psilocybin in preclinical testing, are selected for IND enabling studies [...] ("Mindset" or the "Company"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced that after extensive preclinical screening studies, a lead psychedelic drug clinical candidate, MSP-2020, and a second back-up drug candidate, MSP-2003, have been selected from its Family 2 program in collaboration with The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, to advance to IND enabling studies. [...] MSP-2020 and MSP-2003 are both novel and patentable compounds. They are covered under Mindset's United States Patent and Trademark Office (USPTO) patent number 17/387,864, titled "3-Pyrrolidine-Indole Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders." Mindset has received a notice of allowance from the USPTO for this application. [...] In side-by-side comparisons to psilocybin and psilocin, the two drug candidates elicit in vitro and behavioral responses consistent with a stronger and shorter acting psychedelic effect than psilocybin and a significantly reduced half-life. The drug candidates are CNS penetrant and exhibit high oral bioavailability in different species.
  8. ^Pharma M (February 2021)."Mindset Pharma Inc. Scientific Summary February 2021"(PDF).In Vitro Profile of Selected Mindset Prodrug Candidates
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Tryptamines
4-Hydroxytryptamines
andesters/ethers
5-Hydroxy- and
5-methoxytryptamines
N-Acetyltryptamines
α-Alkyltryptamines
α-Ketotryptamines
Cyclized tryptamines
Isotryptamines
Related compounds
Stub icon

Thishallucinogen-related article is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=MSP-2020&oldid=1334173611"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp